A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia
← catalyst calendarNCT07477704 · readout in 132 d
Sponsored by Regeneron Pharmaceuticals (industry) · REGN — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
420estimated
Sites
34
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-06-17 | actual | When the study began enrolling |
| Primary completion | 2026-12-29 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-02-23 | estimated | The whole study's end, after follow-up |
| First posted | 2026-03-17 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Hypercholesterolemia
Intervention
- Drug: Alirocumab — also filed as Praluent®, REGN727, SAR236553
Primary outcome
what the primary-completion date above is the date OFPercent change in LDL-C
measured From Baseline through Week 12
Permalink · REGN's whole pipeline · Catalyst calendar · Every registered study · What changed